Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated…
- Trial name
- NCT01068860
- Testing
- Canakinumab 150 mg
- Where
- 52 sites in United States, Australia and 5 more
- Volunteers
- 246 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications
The purpose of this study was to investigate the mortality and macrovascular morbidity as well as the incidence of malignancies over time, in high-risk diabetic participants who previously received long-term treatment with either…
- Trial name
- NCT02678676
- Testing
- No Intervention
- Volunteers
- 3,599 people
- Sponsor
- Takeda
Type 2 Diabetes
Sitagliptin and Glucagon Counterregulation
To evaluate the effect of DPP-4 inhibition on glucagon counter-regulatory mechanisms at moderate hypoglycemia in metformin-treated subjects with T2DM
- Trial name
- SITACLAMP (NCT02256189)
- Testing
- Sitagliptin
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- Lund University
Type 2 Diabetes Mellitus
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
The investigators hypothesize that Cana may be able to improve number and function of CD34+ endothelial progenitor cells. The investigators also propose that this expected cardiovascular benefit is independent of HbA1C reduction.
- Trial name
- NCT02964585
- Testing
- Canagliflozin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- George Washington University
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum…
- Trial name
- NCT01778049
- Testing
- BI 10773, BI 10773 / BI 1356
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 708 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Obesity
CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes
This is a prospective, randomized clinical trial for patients with recurrent type 2 diabetes post-gastric bypass surgery that will compare a 6 month course of canagliflozin monotherapy vs.
- Trial name
- NCT02912455
- Testing
- canagliflozin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The Cleveland Clinic
Type 2 Diabetes Mellitus
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Primary Objective: To demonstrate the non-inferiority of once weekly injection of efpeglenatide in comparison to once weekly injection of dulaglutide on glycated hemoglobin (HbA1c) change in participants with Type 2 diabetes…
- Trial name
- AMPLITUDE-D (NCT03684642)
- Testing
- Efpeglenatide, Dulaglutide, Background therapy Metformin
- Where
- 45 sites in United States, Hungary and 2 more
- Volunteers
- 908 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients
Compare the effect of Vildagliptin plus Metformin versus Glimepiride plus Metformin on glucose variability in T2DM patients.
- Trial name
- VARIABLE (NCT01910441)
- Testing
- Vildagliptin, Glimepiride, Metformin
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes.
- Trial name
- AWARD-2 (NCT01075282)
- Testing
- Insulin Glargine, LY2189265, Metformin
- Where
- 78 sites in Argentina, Australia and 18 more
- Volunteers
- 810 people
- Sponsor
- Eli Lilly and Company
Hypertension
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II…
- Trial name
- ViVID (NCT00927394)
- Testing
- Aliskiren, Valsartan
- Where
- 4 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Novartis
Type 2 Diabetes
Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)
To evaluate the effect of treatment with sitagliptin compared to placebo in elderly patients with type 2 diabetes mellitus who have poor glycemic control with diet and exercise.
- Trial name
- NCT00305604
- Testing
- sitagliptin phosphate
- Volunteers
- 206 people
- Sponsor
- Merck Sharp & Dohme LLC
Type2 Diabetes
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics
This study allows Type 2 diabetics to receive feedback from a continuous glucose monitor (CGM) as part of an educational program designed to help them better manage their glucose levels.
- Trial name
- CGM_IRB2 (NCT03252964)
- Testing
- Continuous Glucose Monitor (CGM), Activity Tracker, Coaching
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Savvysherpa, Inc.
Diabetes Mellitus, Type 2
4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
Primary objective: safety and tolerability of BI 10773 in male and female patients with type 2 diabetes Secondary objective: pharmacokinetics and pharmacodynamics of BI 10773
- Trial name
- NCT00558571
- Testing
- BI 10773 low dose, BI 10773 medium dose, BI 10773 high dose
- Where
- 3 sites in Germany
- Volunteers
- 78 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Evaluating an Analogy-Based Consultation Approach for Insulin-Treated Type 2 Diabetes Patients
The goal of this retrospective interventional study is to learn whether a new consultation approach called M2-PRIME can help improve blood sugar control in people with type 2 diabetes who use insulin and have high blood sugar…
- Trial name
- ANALOGIES01 (NCT07265245)
- Testing
- M2-PRIME
- Where
- Malaysia
- Volunteers
- 106 people
- Sponsor
- Ministry of Health, Malaysia
Diabetes Mellitus
Risk Identification of the GlucoTab System in Routine Use
Identification of risks of the GlucoTab system in routine use.
- Trial name
- NCT02053077
- Where
- Austria
- Volunteers
- 150 people
- Sponsor
- Medical University of Graz
Diabetes Mellitus, Non-Insulin-Dependent
Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)
After 24 weeks of treatment, to assess the A1C-lowering efficacy of sitagliptin 100 mg once daily added to the regimen of patients with inadequate glycemic control on metformin monotherapy
- Trial name
- NCT00875394
- Testing
- sitagliptin phosphate, Comparator: metformin, Comparator: Antidiabetic Standard of Care
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Type 2, Diabetes Mellitus
Cryovagotomy Diabetes Trial
The pilot study will assess the feasibility and efficacy of cryoablation procedure to freeze the vagus nerve in obese patients with type 2 diabetes. Aim 1 will focus on changes in glycemic control.
- Conditions
- Diabetes Type 2, Diabetes Mellitus, Obesity
- Trial name
- NCT04276051
- Testing
- Cryoablation of the Vagus Nerve, Lifestyle Intervention
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.
- Trial name
- SURPASS-3 (NCT03882970)
- Testing
- Tirzepatide, Insulin Degludec
- Where
- 122 sites in United States, Argentina and 11 more
- Volunteers
- 1,444 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Long-term Study on the Side Effects of TRADIANCE in Japanese Patients With Type 2 Diabetes
Study objectives is to investigate the safety of long-term daily use of TRADIANCE® Combination Tablets AP and BP in Japanese patients with Type 2 Diabetes mellitus (T2DM) used in routine care.
- Trial name
- NCT03761797
- Testing
- TRADIANCE® Combination Tablets AP, TRADIANCE® Combination Tablets BP
- Where
- Japan
- Volunteers
- 1,164 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Local Anesthesia
Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2
The purpose of this study is to determine whether 2% lidocaine (L) + clonidine (C) (15 mcg/ml) as a vasoconstrictor achieves efficient (equal or better parameters of intraoral local anesthesia in comparison to 2% lidocaine +…
- Trial name
- LCIOADMT2 (NCT02371759)
- Testing
- L+C maxillary anesthesia, L+C mandibular anesthesia, L+E maxillary anesthesia
- Where
- Serbia
- Volunteers
- 256 people
- Sponsor
- University of Belgrade